Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia

NCT03291353 is registered in ClinicalTrials.gov with Michael Boyiadzis as lead sponsor.

NCT NCT03291353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03291353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
Lead sponsor
Michael Boyiadzis
Phase
Phase 1
Overall status
Withdrawn
Start date
October 17, 2017
Completion date
August 19, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory acute myeloid leukemia